Literature DB >> 25445946

The right ventricle in pulmonary arterial hypertension.

Robert Naeije1, Alessandra Manes2.   

Abstract

Pulmonary arterial hypertension (PAH) is a right heart failure syndrome. In early-stage PAH, the right ventricle tends to remain adapted to afterload with increased contractility and little or no increase in right heart chamber dimensions. However, less than optimal right ventricular (RV)-arterial coupling may already cause a decreased aerobic exercise capacity by limiting maximum cardiac output. In more advanced stages, RV systolic function cannot remain matched to afterload and dilatation of the right heart chamber progressively develops. In addition, diastolic dysfunction occurs due to myocardial fibrosis and sarcomeric stiffening. All these changes lead to limitation of RV flow output, increased right-sided filling pressures and under-filling of the left ventricle, with eventual decrease in systemic blood pressure and altered systolic ventricular interaction. These pathophysiological changes account for exertional dyspnoea and systemic venous congestion typical of PAH. Complete evaluation of RV failure requires echocardiographic or magnetic resonance imaging, and right heart catheterisation measurements. Treatment of RV failure in PAH relies on: decreasing afterload with drugs targeting pulmonary circulation; fluid management to optimise ventricular diastolic interactions; and inotropic interventions to reverse cardiogenic shock. To date, there has been no report of the efficacy of drug treatments that specifically target the right ventricle. ©ERS 2014.

Entities:  

Mesh:

Year:  2014        PMID: 25445946     DOI: 10.1183/09059180.00007414

Source DB:  PubMed          Journal:  Eur Respir Rev        ISSN: 0905-9180


  55 in total

1.  Vorticity is a marker of diastolic ventricular interdependency in pulmonary hypertension.

Authors:  Michal Schäfer; James Browning; Joyce D Schroeder; Robin Shandas; Vitaly O Kheyfets; J Kern Buckner; Kendall S Hunter; Jean R Hertzberg; Brett E Fenster
Journal:  Pulm Circ       Date:  2016-03       Impact factor: 3.017

2.  Clinical Evaluation of Exercise Capacity in Adults with Systemic Right Ventricle.

Authors:  Beata Rog; Kinga Salapa; Magdalena Okolska; Natalia Dluzniewska; Piotr Werynski; Piotr Podolec; Lidia Tomkiewicz-Pajak
Journal:  Tex Heart Inst J       Date:  2019-02-01

3.  Right Ventricular Fiber Structure as a Compensatory Mechanism in Pressure Overload: A Computational Study.

Authors:  Arnold D Gomez; Huashan Zou; Megan E Bowen; Xiaoqing Liu; Edward W Hsu; Stephen H McKellar
Journal:  J Biomech Eng       Date:  2017-08-01       Impact factor: 2.097

4.  Altered synchrony of right ventricular contraction in borderline pulmonary hypertension.

Authors:  Bouchra Lamia; Jean-François Muir; Luis-Carlos Molano; Catherine Viacroze; Jacques Benichou; Philippe Bonnet; Jean Quieffin; Antoine Cuvelier; Robert Naeije
Journal:  Int J Cardiovasc Imaging       Date:  2017-03-19       Impact factor: 2.357

5.  Inhaled combination of sildenafil and rosiglitazone improves pulmonary hemodynamics, cardiac function, and arterial remodeling.

Authors:  Jahidur Rashid; Eva Nozik-Grayck; Ivan F McMurtry; Kurt R Stenmark; Fakhrul Ahsan
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-10-11       Impact factor: 5.464

6.  Heart-lung interactions, a long story with many pioneers.

Authors:  Didier Payen
Journal:  Ann Transl Med       Date:  2018-09

Review 7.  MicroRNAs: pleiotropic players in congenital heart disease and regeneration.

Authors:  Sarah C Hoelscher; Stefanie A Doppler; Martina Dreßen; Harald Lahm; Rüdiger Lange; Markus Krane
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

8.  A pressure-based single beat method for estimation of right ventricular ejection fraction: proof of concept.

Authors:  Paul M Heerdt; Vitaly Kheyfets; Sofia Charania; Ahmed Elassal; Inderjit Singh
Journal:  Eur Respir J       Date:  2020-03-12       Impact factor: 16.671

Review 9.  Novel putative pharmacological therapies to protect the right ventricle in pulmonary hypertension: a review of current literature.

Authors:  Gerald J Maarman; Rainer Schulz; Karen Sliwa; Ralph Theo Schermuly; Sandrine Lecour
Journal:  Br J Pharmacol       Date:  2017-02-24       Impact factor: 8.739

Review 10.  The molecular rationale for therapeutic targeting of glutamine metabolism in pulmonary hypertension.

Authors:  Thomas Bertero; Dror Perk; Stephen Y Chan
Journal:  Expert Opin Ther Targets       Date:  2019-05-11       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.